Introduction: Hepatitis B virus (HBV) is the most common aetiological factor causing hepatocellular carcinoma (HCC). HBx gene plays an enigmatic role in HBV-related HCC. In this study we have analysed amino acid substitutions in HBx from HBV-infected individuals of different clinical stages. Materials and Methods: HBV-infected individuals (n = 93) were recruited in the study. DNA was extracted from plasma, amplified, and DNA sequencing was performed using specific primers targeting HBx gene (540 bp). Results: Among the study participants, 57% had chronic HBV infection, 30% had chronic liver disease (CLD) and 13% had HBV related HCC. Genotypes such as D1, D2, D3, A1, C2 and B2 were identified of which genotype D2 was predominant (78%). HBxC-terminal deletion was observed in four hepatitis B e antigen (HBeAg) negative participants with CLD. The frequency of aminoacid substitution in proapoptotic domain was higher in HBeAg negative participants including I127V (34%), K130M (34%), V131I (40%). The frequency of double mutation (K130M+V131I) and triple mutation (I127V+K130M+V131I) were found to be higher (32% and 36%) in HBeAg negative participants. Also, we identified L5M substitution (4.3%) in HBeAg positive participants with advanced liver disease. Conclusion: In HBx gene, aminoacid substitutions at positions 127, 130, 131 are associated with poor expression of HBeAg. We suggest screening for HBx aminoacid substitutions especially in patients with HBeAg negative chronic HBV infection to predict the clinical outcome and enable early treatment to prevent disease progression.
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IntroductIon
Globally, there are about 257 million chronic carriers of hepatitis B virus (HBV) as of 2017. India has the second largest burden with an intermediate prevalence of 4% chronic HBV carriers. [1] Two third of the burden is reported to be due to hepatitis e antigen (HBeAg) negative patients. HBV related hepatocellular carcinoma (HCC) burden in South India is about 42%. [2] There are many factors that contribute to the development of HCC such as HBV/hepatitis C virus (HCV), alcoholic liver disease and non-alcoholic fatty liver disease. Among these, HBV is the most common etiological factor of HCC in India. The prognosis of HBV related HCC is extremely poor with a survival rate of <16 months. The HBV genome comprises of an incomplete double stranded circular structure containing 4 overlapping open reading frames encoding proteins such as surface (S), core protein (C), polymerase protein (P) and X protein (X). X-gene is the smallest gene with a size of 540 bp encoding a small protein with 154 aminoacids. HBx protein is a multifunctional transactivator protein which regulates viral and cellular proteins. It is highly conserved and essential for viral replication. The X-gene overlaps the C-terminus of the polymerase gene that encodes for reverse transcriptase protein and N-terminus of the core-gene that encodes for core protein. Depending upon the site of mutation in X-gene, mutations can affect two genes such as core gene and a partial segment of polymerase gene simultaneously. The mutations in pre-core region encoding HBeAg is associated with an increased risk of HCC. [3] HBx gene point mutations can modulate the expression of HBeAg and either increase or decrease the viral replication capacity. T1762/A1764 double mutation is associated with the risk of HCC. [4] The core promoter (CP) and the enhancer II (Enh II) genes are located in the region that overlaps X gene. HBx proteins interfere with several signaling pathways associated with cell proliferation and invasion. HBxC-terminal truncation has been reported to impact the development of HCC. [5] As a transactivator, HBx can affect regulatory non-coding RNAs and mRNA. HBx interacts with various signal transduction pathways such as p53, Wnt, nuclear factor kappa B. HBx hastens the development of HCC. HBx function in HCC are nuclear translocation, protein-protein interactions, regulation of transcription factors, and induction of chromosome instability. [6] HBx involves in signal transduction and results in cell proliferation, transformation, invasion and metastasis. The present study aimed to investigate HBx mutations in chronic HBV carriers in different clinical phases of infection.
materIals and methods
Ethics statement
This is a cross sectional study and was conducted from March 2016 to January 2019 after obtaining Institutional Ethics Committee approval (IEC-NI/16/AUG/55/55).
Study subjects
Adult chronic HBV carriers (n = 93) evidenced as chronic hepatitis and with plasma HBV DNA levels >2000 IU/ml. All the study subjects were seronegative for HIV and HCV. The participant's HBeAg, and serum alanine transaminase (ALT) levels were retrieved from the patient's hospital records.
Study settings
Patients attending medical gastroenterology clinic of our tertiary care center were directed to Molecular biology and clinical virology section under Department of Microbiology for the estimation of plasma HBV DNA levels by real time quantitative polymerase chain reaction (PCR).
Sample collection and processing
After obtaining written informed consent, 5 ml blood was collected in ethylenediaminetetraacetic acid vacutainers from 93 participants. Plasma was separated from the whole blood immediately after collection and stored at −80°C in multiple aliquots for further analysis.
DNA extraction and quantitative real time polymerase chain reaction
DNA was extracted from the plasma samples using QIAamp DNA Blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instruction. Plasma HBV DNA levels were quantified using Artus HBV RG PCR assay (Qiagen, Hilden, Germany) in Rotorgene Q-5 plex system (Qiagen, Hilden, Germany).
Quality control measures
Appropriate quality control measures were taken including inclusion of sterile water as negative control and positive control in each assay. Estimate of HBV DNA of the samples was performed only after the interpretation of positive and negative controls. Positive control was an in-house control with a 2 log 10 IU/ml HBV DNA (CV% -3.6). The laboratory is accredited by national accredited board of laboratories (NABL) for detection of HBV by real time PCR and our laboratory participates in IAMM EQAS.
Hepatitis B virus X-gene nested polymerase chain reaction
First round of amplification was performed using hot start master mix kit (Qiagen, Hilden, Germany) along with outer primers 5'-TGC CAA GTG TTT GCT GAC GC-3' and 5'-ACG GGA AGA AAT CAG AAG G-3' and 10 µL of the extracted DNA. The reaction volume was adjusted to 50 µL by adding milli Q water. The amplification conditions included an initial activation at 95°C for 15 min; followed by 45 cycles of 94°C for 1 min, 45°C for 1 min, 72°C for 2 min and the final extension was 72°C for 10 min. [7] Round II was carried out with 2 µL of first round PCR product in hotstart master mix along with inner primers 5'-GCC GAT CCA TAC TGC GGA ACT-3' and 5'-GGC ACA GCT TGG AGG CTT GAA-3' with final reaction volume of 50 µL. The cycling conditions were 95°C 15 min; 94°C 1 min, 45°C 1 min, 72°C 2 min for 45 cycles; and finally 72°C for 10 min. [7] 
Agarose gel electrophoresis
The amplified products were analyzed in ethidium bromide stained 2% agarose gel under UV transilluminator. The amplified product size of 540 bp was considered positive.
DNA purification and sequencing
The amplified DNA was filtered using vacuum in the Multiscreen HTS PCR plate (Millipore, USA). Cycle sequencing reactions was carried out using big dye terminator kit (V 3.1) and inner primers. Post-PCR purification was performed with Montage SEQ 96 filtration (Millipore, USA). The purified products were sequenced by Sanger's method on ABI genetic analyzer 3730 platform (Applied Biosystems, USA).
Sequence analysis
The DNA sequences were obtained bi-directionally from forward and reverse primers. The consensus was prepared using sequencher software (Version 5.4.6, Gene Codes Corporation, Michigan, USA). Bioedit Version, 3.2.1, USA) was used to identify the aminoacid substitution.
Phylogenetic analysis
DNA sequences (HBV X gene) of all the genotype (A-H) were retrieved from the Genbank database. The study sequences (n = 93) along with Genbank sequences were included for the analysis. Multiple sequence alignment was performed using in-built ClustalW integrated in MEGA X using 1000 replicates bootstrap testing by neighbor joining method. The positions containing gaps and missing data were eliminated.
Statistical analysis
Data analysis such as median, inter quartile range were performed using Microsoft-excel version (14.0.4760.100). The correlation co-efficient calculation was performed between the plasma HBV DNA level and ALT levels. Kruskal-Wallis test was used to identify the frequency of mutations. All the analysis were carried out using Medcalc Statistical Software (Version 18.2.1, Ostend, Belgium).
Genbank submission
The DNA sequences obtained from the study were submitted to Genbank and the accession numbers are MN066375-MN066411, MN182657-MN182693.
results
In all 93 study participants, 40 participants were HBeAg positive and 53 were HBeAg negative. All the study participants were analyzed for X mutations (1-132 aminoacids) using nested PCR. The median (interquartile range [IQR]) age of study participants was 49 (38-62) years. Among them 82% (n = 73) were male and the rest 18% (n = 20) were female. The median (IQR) plasma HBV DNA level was 5.99 log 10 IU/ml (4.43 log 10 IU/ml-6.88 log 10 IU/ml).
Hepatitis B e antigen positive group
The median age was found to be 52 (35.7-64.2) years. The median plasma HBV DNA level was found to be 6.15 log 10 IU/mL(4.64 log 10 IU/mL-7.56 log 10 IU/mL). The participants were in different stages of disease including 62.5% (n = 25) with chronic HBV infection, 22.5% (n = 9) with chronic liver disease (CLD), 15% (n = 6) were diagnosed with HCC [Table 1 ]. Amino acid substitutions in proapoptotic domain of HBx protein were seen 52Y (n = 1), S64T (n = 1) with participants with CLD. S101 L/P was noted in two individuals with HCC. A102V was detected in 15/40 (37.5%), of which 2 had HCC, 5 had CLD, 8 had chronic HBV infection. T105M was detected in one individual with CLD. M103A was identified in one individual with chronic HBV infection. L123S was observed in one individual with CLD. I127T was detected in 8/40 (20%) participants. K130M was detected in 9/40 (22.5%) participants, V131T was detected in 10/40 (25%).
Hepatitis B e antigen negative group
Among the HBeAg negative study participants (n = 53), the median age was 49 (40-61) years. The median plasma HBV DNA level was 5.65 log 10 IU/mL (4.26 log 10 IU/m-6.4 log 10 IU/mL). The disease spectrum of the participants includes, chronic HBV infection seen in 53% (n = 28) participants, 36% (n = 19) with CLD, 11% (n = 6) HCC [ Table 1 ]. In the proapoptotic domain, H94Y was detected in two participants with HCC. L98I was detected in one participant. S101P was detected in three (5.6%) participants. A102V, I127V, K130M were identified in 18/53 (34%) participants. V131T was identified in 21/53 (40%) participants.
The median plasma HBV DNA level was less in HBeAg negative participants (P = 0.029). The correlation between plasma HBV DNA levels and ALT levels were found to be statistically significant (r = 0.13, P = 0.0033) among the HBeAg positive participants. The frequency of mutations, I127T, K130M and V131 L were high among HBeAg negative participants and were statistically significant. F132Y was observed in two participants with HBeAg negative chronic hepatitis and one participant with CLD [Table 2a ].
Phylogenetic analysis
Phylogenetic analysis of the study participants revealed the presence of D2 genotype in 73 participants (78%), primarily from Tamil Nadu and Andhra Pradesh. D3 was identified in six participants (6.4%) from West Bengal, A1 in seven participants (7.5%) from Tamil Nadu, Delhi and Bihar, C2 was detected in four participants (4.3%) from West Bengal, D1 was identified in two participants (2.1%) from Tamil Nadu and B2 (2.1%) was identified from two participants residing in Chennai [ Figure 1 ].
Double and triple mutations
We have identified HBxC-terminal deletion (92-132 aminoacids) in four HBeAg negative participants with CLD. L5M which is an independent predictor of HCC [7] was identified in 3 participants with HCC and one participant with CLD [ Figure 2 ]. We have also detected double mutations and triple mutations in HBx protein (K130M+V131I) in 26.9% (n = 24) participants of which 71% (n = 17) were HBeAg negative. Among the HBeAg positive participants (K130M+V131I) was detected among participants with CLD and HCC. (I127V+K130M+V131I) triple mutation was detected in 21.3% (n = 19), of which 79% (n = 15) were found among HBeAg negative participants. Other Table 2b ]. Genotype specific aminoacid substitutions identified among the study participants are listed [ Table 3 ]. The aminoacid substitution in the HBV X gene and their role are shown in Figure 3 .
dIscussIon
HBx protein is multifunctional and has a mysterious role in infection and replication of HBV in hepatocytes. It regulates virus and host genes since it does not have DNA binding activity. [8, 9] C-terminus of X gene is truncated for integration and promotes oxidative stress, damages the mitochondrial DNA which leads to HCC. [10, 11] We have noted a 40 amino acids deletion in 3'C-terminal proapoptotic domain among four HBeAg negative participants with CLD.
Five mutations such as H94Y in Enh II binding site of the HBx protein, I127T, K130M, V131I in BH3-like motif and F132Y/I/R are reported to be the associated risk factors of HCC and may promote progression of liver impairment. [12, 13] K103M and V131I mutations are present in CP region which decreases the expression of HBeAg. In our study, H94Y was identified in one participant with HCC and F132I in three participants of which two had chronic HBV infection and one CLD. H94 L and F132I/Y/R are reported to be higher in HCC. [14] Frequency of I127T in genotype D was higher in participants with HCC (70%) than in the CLD group (42.8%) which corroborates with earlier reports. [12] In HBx protein, aminoacids from 52 to 65 and 88-154 domain are important in the transactivation, transcription and replication of HBV genome. [15] We identified H52Y and S64T from patients suffering from CLD. In our study T36A was noted in four participants with CLD. Among those four, three belonged to genotype D and one is genotype B.
T36A and G50R aminoacid substitutions were associated with HCC. [16] In our study 27% had (K130M+V131I) double mutation. We have also noted higher frequency (19%) of K130M+V131I among HBeAg negative participants. This was reported to be ND ND 21 (100) ND ND ND 2 (100) 2 (100) 2 (100) ND Percentages were given in parenthesis. These amino acid substitutions were not detected in individuals infected with genotype C. ND: Not detected
